Pacific Edge shares fall 63% after Novitas decision

Pacific Edge shares fall 63% after Novitas decision
(Image: Pacific Edge)
Rebecca Howard
Cancer diagnostics company Pacific Edge has come out swinging against a decision by Novitas, the Medicare administrative contractor with jurisdiction for its US laboratory, that would end reimbursement for Cxbladder Triage, Detect and Monitor. The shares fell 63% to $0.050 in early trading Monday after a trading halt was lifted.According to Pacific Edge, Novitas continues to misunderstand the current standard of care in evaluating hematuria patients, fails to consider new peer-reviewed evidence and repeats its flawed analysis of the existi...

More Markets

NZ sharemarket edges higher as F&P Healthcare weighs on gains
Markets Market Close

NZ sharemarket edges higher as F&P Healthcare weighs on gains

The S&P/NZX 50 Index closed 14.49 points or 0.11% down at 13,391.59.

Contact Energy expands global investor base
Markets

Contact Energy expands global investor base

Contact Energy priced an inaugural €500 million (NZ$1.01b) 7-year senior bond under its Euro Medium Term Note (EMTN) Programme, it said Friday.“This marks a milestone in Contact’s funding strategy, expanding our global investor base and reinforcing our commitment to sustainable f...

Kiwibank wary of capital-review barrier to growth
Finance

Kiwibank wary of capital-review barrier to growth

Kiwibank raises issues of competitive advantage.

Fonterra windfall brings risks: ASB
Primary Sector

Fonterra windfall brings risks: ASB

Farmers will vote for the Lactalis deal on Oct 30.